IP Verse

Direct Compression Formulation And Process - EP3023095

The patent EP3023095 was granted to Novartis on Nov 8, 2023. The application was originally filed on Jan 17, 2005 under application number EP15199440A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3023095

NOVARTIS
Application Number
EP15199440A
Filing Date
Jan 17, 2005
Status
Patent Maintained As Amended
Oct 6, 2023
Grant Date
Nov 8, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

INNOVATE LEGAL SERVICESFeb 15, 2019CURLEYADMISSIBLE
COOKEFeb 15, 2019ELKINGTON AND FIFEWITHDRAWN
INTAS PHARMACEUTICALSFeb 15, 2019HOFFMANN EITLEWITHDRAWN

Patent Citations (90) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20010788173
DESCRIPTIONUS20040427404
DESCRIPTIONDE10256264
DESCRIPTIONDE19616486
DESCRIPTIONEP1245568
DESCRIPTIONEP1258476
DESCRIPTIONEP1258480
DESCRIPTIONUS2003087950
DESCRIPTIONUS2003096846
DESCRIPTIONUS2003096857
DESCRIPTIONUS2003216450
DESCRIPTIONUS2003225102
DESCRIPTIONUS6107317
DESCRIPTIONUS6110949
DESCRIPTIONUS6124305
DESCRIPTIONUS6166063
DESCRIPTIONUS6395767
DESCRIPTIONUS6482844
DESCRIPTIONWO0034241
DESCRIPTIONWO0134594
DESCRIPTIONWO0152825
DESCRIPTIONWO0155105
DESCRIPTIONWO0168603
DESCRIPTIONWO0172290
DESCRIPTIONWO0181337
DESCRIPTIONWO0197808
DESCRIPTIONWO0202560
DESCRIPTIONWO02051836
DESCRIPTIONWO02053548
DESCRIPTIONWO02062764
DESCRIPTIONWO02066627
DESCRIPTIONWO02067918
DESCRIPTIONWO02068420
DESCRIPTIONWO02076450
DESCRIPTIONWO02083109
DESCRIPTIONWO02083128
DESCRIPTIONWO0214271
DESCRIPTIONWO0230890
DESCRIPTIONWO0238541
DESCRIPTIONWO03000180
DESCRIPTIONWO03000181
DESCRIPTIONWO03000250
DESCRIPTIONWO03002531
DESCRIPTIONWO03002553
DESCRIPTIONWO03002593
DESCRIPTIONWO03002942
DESCRIPTIONWO03003727
DESCRIPTIONWO03004496
DESCRIPTIONWO03004498
DESCRIPTIONWO03024942
DESCRIPTIONWO03024965
DESCRIPTIONWO03032950
DESCRIPTIONWO03035057
DESCRIPTIONWO03035067
DESCRIPTIONWO03037327
DESCRIPTIONWO03057200
DESCRIPTIONWO03068757
DESCRIPTIONWO03074500
DESCRIPTIONWO2004024184
DESCRIPTIONWO2004037169
DESCRIPTIONWO2004037181
DESCRIPTIONWO2004052850
DESCRIPTIONWO2004071454
DESCRIPTIONWO2004076433
DESCRIPTIONWO9310127
DESCRIPTIONWO9515309
DESCRIPTIONWO9529691
DESCRIPTIONWO9818763
DESCRIPTIONWO9819998
DESCRIPTIONWO9925719
DESCRIPTIONWO9938501
DESCRIPTIONWO9946272
DESCRIPTIONWO9961431
DESCRIPTIONWO9967278
DESCRIPTIONWO9967279
OPPOSITIONEP1537880
OPPOSITIONEP1715893
OPPOSITIONJP2003327532
OPPOSITIONUS2003078247
OPPOSITIONUS2003087950
OPPOSITIONUS6548481
OPPOSITIONWO0034241
OPPOSITIONWO0152825
OPPOSITIONWO03101448
OPPOSITIONWO2004024184
OPPOSITIONWO2004092127
SEARCHJP2003327532
SEARCHUS2003078247
SEARCHUS6548481
SEARCHWO0034241

Non-Patent Literature (NPL) Citations (45) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- A.H.KIBBE, Handbook of pharmaceutical excipients. 3rd ed., AMERICAN PHARMACEUTICAL ASSOCIATION
DESCRIPTION- "Chapter 3: SIZE REDUCTION", H.A.LIEBERMAN, L.LACHMAN, J.B.SCHWARTZ, Pharmaceutical dosage forms. 2nd ed, vol. 2
DESCRIPTION- DIABETES, (1998), vol. 47, pages 1253 - 1258
DESCRIPTION- H.A.LIEBERMAN, L.LACHMAN, J.B.SCHWARTZ, Pharmaceutical dosage forms, vol. 2, page 187
DESCRIPTION- H.U. DEMUTH ET AL., J. ENZYME INHIBITION, (1988), vol. 2, pages 129 - 142
DESCRIPTION- MONA PATEL, EXPERT OPINION INVESTIG DRUGS, (200304), vol. 12, no. 4, pages 623 - 633
DESCRIPTION- RAYMOND C ROWE, Handbook of Pharmaceutical Excipients. 4th ed., SCIENCE AND PRACTICE
DESCRIPTION- T. ALLEN, Particle Size Measurement, CHAPMAN & HALL, (1997), vol. 1, page 178
DESCRIPTION- WALLACE T. ASHTON, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2004), vol. 14, pages 859 - 863
OPPOSITION- "11 Particle-size reduction", M E Aulton, Pharmaceutics second edition, pages 166 - 180, 405, XP055565073
OPPOSITION- AHMAD et al., "Effect of Moisture on the Stability of Packaged Paracetamol Tablet Formulations", Pakistan J. Pharm. Sci., (20030000), vol. 16, no. 2, pages 13 - 16
OPPOSITION- AKERS M. et al., "Preformulation Testing of Solid Oral Dosage Form Drugs", Canadian J Pharm Sci, (19760000), vol. 11, no. 1, pages 1 - 10, XP055565262
OPPOSITION- anonymous, "Avicel®", DuPont - Product specification, (20050000), URL: https://www.pharma.dupont.com/pharmaceutical-products/avicelr-for-solid-dose-forms.html, XP055570284
OPPOSITION- ANSEL et al., "Capsules and Tablets", Pharmaceutical Dosage Forms and Drug Delivery Systems, (19990000), pages 196, 209, 216 - 217, XP055565061
OPPOSITION- "cellulose microcrystalline", Kibbe, A. H et al, Handbook of Pharmaceutical Excipients, (20000000), pages 102 - 106, 276-285, 305-308, 501-504, XP055566535
OPPOSITION- "chapter 16", Alfred Martin et al, Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences, Philadelphia, (19930000), vol. 1, pages 331 , 423 - 436, XP055566540
OPPOSITION- "chapter 92", Gennaro, A. R, Remington: The Science and Practice of Pharmacy, (19950000), vol. 2, pages 1616 - 1627, XP055566526
OPPOSITION- "Diprophyllin-Injektionsläsung 100 mg/nl - Dissimilation", Hunnius Pharmazeutisches Worterbuch, (19980000), pages 424 - 425, XP055565291
OPPOSITION- "Direct Compression", Parikh D. M., Handbook of Pharmaceutical Granulation Technology, Marcel Dekker, (19970000), page 102, ISBN 0-8247-9882-1, XP055570290
OPPOSITION- "Dissolution", Gennaro, Remington: The Science and Practice of Pharmacy, (19950000), vol. 1, page 595, XP055282825
OPPOSITION- "Gelbe Liste Identa 2004 15 Ausgabe", Medi Media, (20030000), pages FP - 83, XP055565221
OPPOSITION- "General Monographs Tablets", British Pharmacopoeia, vol. II, page 753, XP055565110
OPPOSITION- Handbook of Pharmaceutical Excipients third edition, (20000000), pages 102 - 106, 276-285, 305-308, 500-504, XP055565140
OPPOSITION- Harry G Brittain, "Chapter 1 and 5", Harry G Brittain, Harry G Brittain, Physical Characterization of Pharmaceutical Solids, (19950000), pages 1 - 35,157-185, XP055565275
OPPOSITION- KARIN LILTORP, Determination of Particle Sizes.in the Pharmaceutical Industry, (20140000), pages 10, 28-29,54 - 55, ISBN 978-87-7145-657-8, XP003035359
OPPOSITION- LACHMAN et al., "Factors Affecting Drug Absorption", The Theory and Practice of Industrial Pharmacy, (19860000), pages 221 - 222, XP003032295
OPPOSITION- LACHMAN et al., "Tablets - Chapter 12", The Theory and Practice of Industrial Pharmacy, (19700000), pages 305 - 319,326-327, XP055297952
OPPOSITION- LIEBERMAN et al., "4 Compressed Tablets by Direct Compression", Pharmaceutical Dosage Forms: Tablets, vol. 1, pages 195 - 220, XP055565054
OPPOSITION- LIEBERMAN et al., "Preformation Testing", Pharmaceutical Dosage Forms, vol. 1, pages 1 - 4, XP003021160
OPPOSITION- MARTIN et al., "16 Micromeritics", Physical Pharmacy, pages 331,423 - 427, 429-436, XP055565100
OPPOSITION- M. E. Aulton, "Pharmaceutics: The Science of Dosage Form Design. 2nd ed.", Churchill Livingstone, ISBN 0-443-05517-3, (20020000), pages 431 - 436, URL: Tablets and Compaction, XP055570278
OPPOSITION- "Mesh", Rompp, (19980000), XP055565247
OPPOSITION- Michael E Aulton, Pharmaceutics, 00002002, pages 6 - 7, XP055565127
OPPOSITION- Miller, "A Direct Compression", Handbook Pharmaceutical Granulation Technology, vol. 81, page 102, XP055565064
OPPOSITION- Milo Gibaldi, "Gastrointestinal Absorption - Physicochemical Considerations", Biopharmaceutics and Clinical Pharmacokinetics, (19910000), page 51, XP055355462
OPPOSITION- "performulation testing", Lieberman, H. A. et al, Pharmaceutical Dosage Forms: Tablets, New York, (19890000), vol. 1, pages 5 - 6 , 196 - 200, XP055566532
OPPOSITION- "Preformulation, Mixing, tableting", M. E. Aulton, Pharmaceutics: The Science of Dosage Form Design, Churchill Livingstone, (19880000), pages 247-249, 555-557, 564-580, 600-607, 647 - 661, ISBN 0-443-03643-8, XP055570217
OPPOSITION- "Tablet Dossage Forms", Gilbert S. banker et al, Drugs and Pharmaceutical Sciences. Modern Pharmaceutics. Volume 40, Marcel Dekker, (19900000), pages 355-358, 404 - 405, ISBN 0-8247-7499-X, XP055570198
OPPOSITION- Wadke et al., "1 Preformulation Testing", Wadke et al., LIEBERMAN et al., Pharmaceutical Dosage Forms: Tablets, vol. 1, pages 1 - 24, XP055565212
OPPOSITION- CRAIG D.Q.M, "The mechanisms of drug release from solid dispersions in water-soluble polymers", International Journal of Pharmaceutics, (20020000), vol. 231, no. 2, pages 131 - 144, XP055067696
OPPOSITION- VILLHAUER E.B. et al., "1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties", J. Med. Chem., (20030000), vol. 46, pages 2774 - 2789, XP002714152
OPPOSITION- Villhauer, "Supporting information to 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties", JOURNAL OF MEDICINAL CHEMISTRY, (20030000), vol. 46, no. 13, pages 1 - 18, XP055565090
OPPOSITION- COHEN J. L. et al., "The Development of USP Dissolution and Drug Release Standards", Pharmaceutical Research, (19900000), vol. 7, no. 10, pages 983 - 987, XP009120018
SEARCH- LIEBERMANN H A ET AL, Pharmaceutical Dosage Forms: Tablets, PHARMACEUTICAL DOSAGE FORMS-TABLETS/ ED. 2, XX, XX, PAGE(S) I-II, (19890101), XP003027810 [A] 25 * page 197, paragraph 3 - page 198, paragraph 2 *
SEARCH- EDWIN B VILLHAUER ET AL, "1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 46, no. 13, doi:10.1021/JM030091L, ISSN 0022-2623, (20030101), pages 2774 - 2789, (20030524), XP002663718 [Y] 25 * page 2775 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents